Primary mediastinal large B-cell lymphoma (PMBCL) is an aggressive lymphoma that begins in the chest. When it comes back or stops responding to treatment, CAR T-cell therapy may be an option. SinoUnited Health in Shanghai assesses and treats PMBCL with CAR T-cell therapies approved by China's National Medical Products Administration.
Plain, general information about the disease — the shared starting point before we get to treatment.
Primary mediastinal large B-cell lymphoma is a type of non-Hodgkin lymphoma that starts in the mediastinum — the space in the middle of the chest, between the lungs. It develops from B-cells, a type of white blood cell, and it grows quickly.
It is uncommon, and it is diagnosed more often in younger adults than most other lymphomas — frequently in people in their twenties, thirties and forties, and somewhat more often in women.
Because the lymphoma grows in the chest, the first symptoms often come from the mass pressing on nearby structures: breathlessness, a cough, chest discomfort, or swelling in the face, neck or arms.
Related to DLBCL, and not the same as it — which is why this page exists separately.
PMBCL belongs to a wider group of aggressive lymphomas called large B-cell lymphoma (LBCL). CAR T-cell therapies approved by China's NMPA for relapsed or refractory large B-cell lymphoma name primary mediastinal large B-cell lymphoma among the conditions they treat.
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in that same group. PMBCL and DLBCL are related but distinct conditions — PMBCL sits alongside DLBCL under the large B-cell lymphoma umbrella, not inside it.
If you are looking for information on DLBCL, see our DLBCL page.
Two terms that decide, more than anything else, whether CAR T-cell therapy is on the table.
Relapsed means the lymphoma came back after treatment that had worked. Refractory means it did not respond adequately to treatment in the first place, or stopped responding while treatment was still underway.
Most people with PMBCL are treated first with chemotherapy, often combined with an antibody therapy, and many do well. When PMBCL returns or resists treatment, the options narrow — and that is the point at which CAR T-cell therapy is considered.
Not a first treatment — a later option, targeted at a protein found on B-cells.
CAR T-cell therapy uses a patient's own T-cells. The cells are collected, genetically modified in a laboratory to recognize a marker on the surface of the lymphoma cells, grown in number, and returned by infusion. For PMBCL, the CAR T-cell therapies used are directed at CD19, a protein found on the surface of B-cells.
CAR T-cell therapy is considered after other treatments have been tried.
Three CD19-directed CAR T-cell therapies administered at SinoUnited Health. Which is right for you is decided by the clinical team.
These CAR T-cell therapies are approved by China's NMPA for large B-cell lymphoma (LBCL) — the group of aggressive lymphomas that primary mediastinal large B-cell lymphoma belongs to, alongside DLBCL. Each card below states what that therapy's own approved indication says.
A CD19-directed CAR T-cell therapy, approved by China's NMPA for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The approved indication names primary mediastinal large B-cell lymphoma.
See how CNCT19 works, who it may suit, and what to expectA CD19-directed CAR T-cell therapy, approved by China's NMPA for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The approved indication names primary mediastinal large B-cell lymphoma.
See how Axi-cel works, who it may suit, and what to expectA CD19-directed CAR T-cell therapy, approved by China's NMPA for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The approved indication names primary mediastinal large B-cell lymphoma.
See how Relma-cel works, who it may suit, and what to expectA condition may be treated by more than one therapy, and a therapy may treat more than one condition — each therapy page links back to the conditions it's used for.
Eligibility is assessed from your records — which means you can find out where you stand before traveling.
The following information is for reference only. Final treatment decisions should be made by a qualified physician based on each patient's individual condition.
CAR T-cell therapy at SinoUnited Health may be considered for people with PMBCL who:
Eligibility is decided after a specialist review of your medical records. This is a general guide only — whether CAR-T is right for you is a decision made by a qualified physician after reviewing your individual case.
Kept deliberately separate: what is true of this class of therapy in general, and what SinoUnited provides.
CAR T-cell therapy has side effects that are anticipated and closely monitored — most commonly cytokine release syndrome (CRS), and sometimes neurological effects (ICANS). Most are manageable when caught early, which is why treatment is given as a supervised inpatient stay.
Infusion and recovery take place as a supervised inpatient stay in 100-level laminar-flow rooms, with on-site intensive care available if escalation is ever needed.
Tocilizumab, the standard treatment for severe cytokine release syndrome, is available on site.
5on-site ICUsTreatment happens across two trips to Shanghai, with the manufacturing weeks spent at home.
A first visit of around a week for specialist assessment and to collect your cells by apheresis, on-site.
About 1 week in ShanghaiYour CAR-T therapy is made while you return home.
3 to 4 weeksYou return for lymphodepleting chemotherapy, the infusion, and monitored recovery under the clinical team.
About 3 weeks in ShanghaiThe PMBCL pathway is the same as for other large B-cell lymphomas — specialist assessment, eligibility review, cell collection, manufacturing, lymphodepleting chemotherapy, infusion, and post-treatment monitoring.
Some patients need additional imaging or help managing symptoms if there is a large mass in the chest. That is decided case by case.
About two months from first assessment to the end of treatment, with the manufacturing period spent at home.
See the full step-by-step journey →PMBCL is assessed and treated at SinoUnited Health's CAR T-Cell Therapy Center by Dr. Lily Zhou, M.D., Ph.D., Chief of Hematology — a hematologist with a postdoctoral fellowship at UCSF, 25 publications indexed in PubMed, and peer-reviewed research in CAR T-cell therapy.
Since 2024 the CAR T-Cell Therapy Center has treated more than 35 patients from twelve countries.
SinoUnited is also a member unit of the Ruijin Consortium of Blood Disease, led by Ruijin Hospital, Shanghai Jiao Tong University — one of China's leading hematology collaborations.
Dr. Zhou's publications are cited as evidence of her standing as a published physician. They are not, and must not be read as, a response rate, success rate, or an indication of outcomes across patients.
Read Dr. Zhou's profile
No. Primary mediastinal large B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) are related but distinct conditions. Both belong to a wider group of aggressive lymphomas called large B-cell lymphoma (LBCL); PMBCL sits alongside DLBCL in that group rather than inside it. PMBCL starts in the mediastinum, the space in the middle of the chest, and is diagnosed more often in younger adults. If DLBCL is what you are looking for, see our DLBCL page.
Relapsed means the lymphoma came back after treatment that had worked. Refractory means it did not respond adequately to treatment in the first place, or stopped responding while treatment was still underway. CAR T-cell therapy is considered at that point, after other treatments have been tried.
CAR T-cell therapies approved by China's National Medical Products Administration for relapsed or refractory large B-cell lymphoma name primary mediastinal large B-cell lymphoma among the conditions they treat. An approval is not the same thing as being suitable for treatment: whether CAR T-cell therapy is an option for you is a decision made by a qualified physician after reviewing your individual case.
CAR T-cell therapy is generally considered after at least two prior lines of systemic therapy. Your full history is reviewed by SinoUnited Health's physicians before any decision is made.
CAR T-cell therapy at SinoUnited Health may be considered for people aged 16 and over.
About two months in total, across two trips: a first stay of around a week for assessment and cell collection, then a second stay of around three weeks for the infusion and monitored recovery. The manufacturing weeks in between are spent at home — see the full journey.
CAR T-cell therapy has side effects that are anticipated and closely monitored — most commonly cytokine release syndrome (CRS), and sometimes neurological effects (ICANS). Most are manageable when caught early, which is why treatment is given as a supervised inpatient stay.
At SinoUnited Health, infusion and recovery take place with on-site intensive care available if escalation is ever needed. Tocilizumab, the standard treatment for severe cytokine release syndrome, is available on site.
A remote assessment by SinoUnited's international care team is free, and starts before you travel. Find out whether CAR-T is an option before you plan any trip.
Check eligibility →